Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Long-term intracavernosal injection therapy: treatment efficacy and patient satisfaction


Intracavernosal injection therapy (ICI) was the first pharmacologic treatment in the management of erectile dysfunction. ICI allows for customization of medication composition and concentrations, making it a highly effective treatment with an acceptable side effect profile. The objective was to investigate the long-term results of ICI using validated and non-validated instruments. This is a retrospective, single-institution study of 105 patients (mean age 61.6 ± 11.1) patients using ICI. Mean duration of ICI was 8.4 ± 6.25 years. Pre- and post-treatment patient-reported penile rigidity were 41.1% ± 29.3 and 89.6% ± 13.6, respectively (p < 0.05). Statistical changes were also found in the pre and post International Index of Erectile Function (IIEF) scores (33.0 ± 14.4 and 60.0 ± 12.7, p < 0.05), erectile function (11.5 ± 1.3 and 27.3 ± 0.9, p < 0.05) and satisfaction domains (5.3 ± 1.5 and 8.1 ± 1.1, p < 0.05) of the IIEF. There were no statistical differences in questionnaire outcomes between difficult to treat patients (diabetes or radical prostatectomy) and the remainder of queried patients. Complications were rare and included priapism (7.1%), penile curvature (10%; <30°), bruising (7.6%), and mild penile pain (12.4%). Overall, ICI therapy is safe and effective, and compliance may be augmented by patient education, dosing customization, and cost reduction.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others


  1. Virag R, Becher E, Carrier S, Jardin A, Wagner G. Local pharmacological treatment modalities. In: Jardin A, Wagner G, Khoury S, editors. Erectile dysfunction. Plymouth: Health Publication Ltd; 2000. p. 305–54.

    Google Scholar 

  2. Richter S, Vardi Y, Ringel A, Shalev M, Nissenkorn I. Intracavernous injections: still the gold standard for treatment of erectile dysfunction in elderly men. Int J Impot Res. 2001;13:172–5.

    Article  CAS  Google Scholar 

  3. Goldstein I, Borges F, Fitch W, Kaufman J, Damron K, Moreno J. Rescuing the failed papaverine phentolamine erection: a proposed synergistic action of papaverine phentolamine and prostaglandin E1. J Urol. 1990;143:304A.

    Google Scholar 

  4. Mulhall JP, Jahoda AE, Cairney M, Goldstein B, Leitzes R, Woods J, et al. The causes of patient dropout from penile self-injection therapy for impotence. J Urol. 1999;162:1291–4.

    Article  CAS  Google Scholar 

  5. Linet OI, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group. N Engl J Med. 1996;334:873–7.

    Article  CAS  Google Scholar 

  6. Eardley I, Donatucci C, Corbin J, El-Meliegy A, Hatzimouratidis K, McVary K, et al. Pharmacotherapy for erectile dysfunction. J Sex Med. 2010;7:524–40.

    Article  CAS  Google Scholar 

  7. Kim SC, Chang IH, Jeon HJ. Preference for oral sildenafil or intracavernosal injection in patients with erectile dysfunction already using intracavernosal injection for >1 year. BJU Int. 2003;92:277–80.

    Article  CAS  Google Scholar 

  8. Mulhall JP, Simmons J. Assessment of comparative treatment satisfaction with sildenafil citrate and penile injection therapy in patients responding to both. BJU Int. 2007;100:1313–6.

    Article  Google Scholar 

  9. Kucuk EV, Tahra A, Bindayi A, Onol FF. Erectile dysfunction patients are more satisfied with penile prosthesis implantation compared with tadalafil and intracavernosal injection treatments. Andrology. 2016;4:952–6.

    Article  CAS  Google Scholar 

  10. Alexandre B, Lemaire A, Desvaux P, Amar E. Intracavernous injections of prostaglandin E1 for erectile dysfunction: patient satisfaction and quality of sex life on long-term treatment. J Sex Med. 2007;4:426–31.

    Article  CAS  Google Scholar 

  11. Coombs PG, Heck M, Guhring P, Narus J, Mulhall JP. A review of outcomes of an intracavernosal injection therapy programme. BJU Int. 2012;110:1787–91.

    Article  CAS  Google Scholar 

  12. Nelson C, Hsiao W, Balk E, Narus J, Tal R, Bennett N, et al. Injection anxiety and pain in men using intracavernosal injection therapy after radical pelvic surgery. J Sex Med. 2013;10:2559–65.

    Article  Google Scholar 

  13. Weiss JN, Badlani GH, Ravalli R, Brettschneider N. Reasons for high drop-out rate with self-injection therapy for impotence. Int J Impot Res. 1994;6:171–4.

    CAS  PubMed  Google Scholar 

  14. Althof SE, Turner LA, Levine SB, Risen C, Kursh E, Bodner D, et al. Why do so many people drop out from auto-injection therapy for impotence? J Sex Marital Ther. 1989;15:121–9.

    Article  CAS  Google Scholar 

  15. Sundaram CP, Thomas W, Pryor LE, Ami Sidi A, Billups K, Pryor JL. Long-term follow-up of patients receiving injection therapy for erectile dysfunction. Urology. 1997;49:932–5.

    Article  CAS  Google Scholar 

  16. Sung HH, Ahn JS, Kim JJ, Choo SH, Han DH, Lee SW. The role of intracavernosal injection therapy and the reasons of withdrawal from therapy in patients with erectile dysfunction in the era of PDE5 inhibitors. Andrology. 2014;2:45–50.

    Article  CAS  Google Scholar 

  17. Mulhall JP, Abdel-Moneim A, Abobakr R, Goldstein I. Improving the accuracy of vascular testing in impotent men: correcting hemodynamic alterations using a vasoactive medication re-dosing schedule. J Urol. 2001;166:923–6.

    Article  CAS  Google Scholar 

  18. Albaugh J, Ferrans CE. Patient-reported pain with initial intracavernosal injection. J Sex Med. 2009;6:513–9.

    Article  Google Scholar 

  19. Hsiao W, Bennett N, Guhring P, Narus J, Mulhall JP. Satisfaction profiles in men using intracavernosal injection therapy. J Sex Med. 2011;8:512–7.

    Article  Google Scholar 

  20. Pryor JP, Ralph DJ. Clinical presentations of Peyronie’ s disease. Int J Impot Res. 2002;14:414–7.

    Article  CAS  Google Scholar 

  21. LaRochelle JC, Levine LA. A survey of primary-care physicians and urologists regarding Peyronie’s disease. J Sex Med. 2007;4:1167–73.

    Article  Google Scholar 

  22. Kadioglu A, Sanli O, Akman T, Canguven O, Aydin M, Akbulut F, et al. Factors affecting the degree of penile deformity in peyronie disease: an analysis of 1001 patients. J Androl. 2011;32:502–8.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Ricardo Munarriz.

Ethics declarations

Conflict of interest

Dr Ricardo Munarriz is a consultant for Coloplast. Kevin O’Brien plans to attend an internship with Pfizer.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bearelly, P., Phillips, E.A., Pan, S. et al. Long-term intracavernosal injection therapy: treatment efficacy and patient satisfaction. Int J Impot Res 32, 345–351 (2020).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links